• 29
  • November
    2011

It was reported at a national conference of spine surgeons Thursday, November 3rd that there is an increased cancer risk with a certain bone medication. Infuse, a Medtronic product, was discovered to increase patient cancer risks when used in high doses during spinal fusion procedures. An analysis led by a Stanford University orthopedic surgeon found that cancer was three to five times more likely to develop in spine surgery patients who received a bone growth stimulating agent as a part of their clinical trial. The cancer was found typically within two to three years after the product was implanted.